Improvements in the diagnosis of dystrophinopathies: what have we learnt in these last 20 years?

被引:6
|
作者
Lopez-Hernandez, Luz B. [2 ,3 ]
Luz Ayala-Madrigal, M. [2 ]
van Heusden, Dave [7 ]
Estrada-Mena, Francisco J. [4 ]
Canto, Patricia [3 ]
Sandoval-Ramirez, Lucila [2 ,5 ]
Gomez-Diaz, Benjamin [6 ]
Coral-Vazquez, Ramon M. [1 ,3 ]
机构
[1] IPN, Escuela Super Med, Secc Posgrad, Mexico City 11340, DF, Mexico
[2] Univ Guadalajara, Inst Genet Humana Doctor Enrique Corona Rivera, Guadalajara 44430, Jalisco, Mexico
[3] Inst Seguridad & Serv Sociales Trabajadores Estad, Ctr Med Nacl 20 Noviembre, Mexico City, DF, Mexico
[4] Univ Panamer, Escuela Med, Mexico City, DF, Mexico
[5] Inst Mexicano Seguro Social, Ctr Invest Biomed Occidente, Guadalajara, Jalisco, Mexico
[6] Inst Nacl Rehabil, Mexico City, DF, Mexico
[7] Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Leiden, Netherlands
关键词
Carrier; Duchenne; Dystrophin; Preimplantation genetics; Prenatal diagnosis; DUCHENNE-MUSCULAR-DYSTROPHY; PREIMPLANTATION GENETIC DIAGNOSIS; LINKED DILATED CARDIOMYOPATHY; POLYMERASE-CHAIN-REACTION; IN-SITU HYBRIDIZATION; READING-FRAME RULE; REAL-TIME PCR; PRENATAL-DIAGNOSIS; FEMALE CARRIERS; X-CHROMOSOME;
D O I
10.33588/rn.5204.2010502
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Dystrophinopathies are X-linked genetic disorders caused by mutations in the DMD gene. Genetic tests are of utmost importance for management and genetic counseling of these diseases. However, the complexity of the DMD gene is a challenge for diagnosis. Aim. To describe recent advances in the diagnosis of dystrophinopathies, after 20 years since the firsts molecular assays for genetic screening for these diseases. Development. Currently, a variety of strategies such as automated mutation detection, cell-based methods and high throughput haplotyping have been developed to facilitate diagnosis of dystrophinopathies, carrier detection, prenatal and preimplantation diagnosis. Conclusion. New technologies have improved early detection and optimal management of dystrophinopathies and have established the basis for future molecular medicine. The most significant advances in dystrophinopathy diagnosis are reviewed herein.
引用
收藏
页码:239 / 249
页数:11
相关论文
共 50 条
  • [31] Thirty Years of Monitoring in England - What Have We Learnt?
    Williams, Jim
    CONSERVATION AND MANAGEMENT OF ARCHAEOLOGICAL SITES, 2012, 14 (01) : 442 - 457
  • [32] Management of Vesicoureteral Reflux: What Have We Learned Over the Last 20 Years?
    Lackgren, Goran
    Cooper, Christopher S.
    Neveus, Tryggve
    Kirsch, Andrew J.
    FRONTIERS IN PEDIATRICS, 2021, 9
  • [33] 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
    Le Cesne, Axel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (06) : 11 - 19
  • [34] TRACHOMA - HAVE WE ADVANCED IN THE LAST 20 YEARS
    TABBARA, KF
    INTERNATIONAL OPHTHALMOLOGY CLINICS, 1990, 30 (01) : 23 - 27
  • [35] Ion-chamber response: what have we learnt from 20 years of Monte Carlo?
    Nahum, A. E.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S14 - S15
  • [36] Diagnosis and Treatment of Pulmonary Embolism: What Have We Learned in the Last 50 Years?
    Dalen, James E.
    Alpert, Joseph S.
    AMERICAN JOURNAL OF MEDICINE, 2020, 133 (04): : 404 - 406
  • [37] Fifty years of travel medicine epidemiology: what have we learnt?
    Steffen, Robert
    Wilson, Mary E.
    INTERNATIONAL HEALTH, 2015, 7 (06): : 375 - 376
  • [38] 10 years of BL Lac selection: What have we learnt?
    Marcha, MJM
    MULTIWAVELENGTH AGN SURVEYS, 2004, : 347 - 350
  • [39] 40 years of veterinary papers in JAC - what have we learnt?
    Schwarz, Stefan
    Enne, Virve I.
    van Duijkeren, Engeline
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (10) : 2681 - 2690
  • [40] Five years after the SYNTAX trial: what have we learnt?
    Davierwala, Piroze
    Mohr, Friedrich W.
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2013, 44 (01) : 1 - 3